RT Journal Article
SR Electronic
T1 COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269542
DO 10.1101/2022.01.24.22269542
A1 Elko, Evan A
A1 Nelson, Georgia A
A1 Mead, Heather L
A1 Kelley, Erin J
A1 Verche, Virginia Le
A1 Cardoso, Angelo A
A1 Ely, Jennifer L
A1 Boyle, Annalee S
A1 Piña, Alejandra
A1 Henson, Sierra N
A1 Rahee, Fatima
A1 Keim, Paul S
A1 Celona, Kimberly R
A1 Yi, Jinhee
A1 Settles, Erik W
A1 Yu, George C
A1 Morris, Sheldon R
A1 Zaia, John A
A1 Ladner, Jason T
A1 Altin, John A
YR 2022
UL http://medrxiv.org/content/early/2022/01/25/2022.01.24.22269542.abstract
AB The COVID-19 pandemic has triggered the first widespread vaccination campaign against a coronavirus. Most vaccinated subjects are naïve to SARS-CoV-2, however almost all have previously encountered other coronaviruses (CoVs) and the role of this immunity in shaping the vaccine response remains uncharacterized. Here we use longitudinal samples and highly-multiplexed serology to identify mRNA-1273 vaccine-induced antibody responses against a range of CoV Spike epitopes and in both phylogenetically conserved and non-conserved regions. Whereas reactivity to SARS-CoV-2 epitopes showed a delayed but progressive increase following vaccination, we observed distinct kinetics for the endemic CoV homologs at two conserved sites in Spike S2: these became detectable sooner, and decayed at later timepoints. Using homolog-specific depletion and alanine-substitution experiments, we show that these distinctly-evolving specificities result from cross-reactive antibodies as they mature against rare, polymorphic residues within these epitopes. Our results reveal mechanisms for the formation of antibodies with broad reactivity against CoVs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NIAID (U24AI152172, U24AI152172-01S1, U24AI152172-IOF, PI: J.A.A.), the California Institute for Regenerative Medicine (CLIN2COVID19-11775, PI: J.A.Z), the State of Arizona Technology and Research Initiative Fund (TRIF, administered by the Arizona Board of Regents, through Northern Arizona University), the Flinn Foundation, and The Cowden Endowment for Microbiology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of The Translational Genomics Research Institute (TGen) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors